US 7,465,808 B2
CCK-1 receptor modulators
Terrance D. Barrett, Encinitas, Calif. (US); J. Guy Breitenbucher, Escondido, Calif. (US); Laurent Gomez, San Diego, Calif. (US); Michael D. Hack, San Diego, Calif. (US); Liming Huang, San Diego, Calif. (US); Kelly J. McClure, San Diego, Calif. (US); Magda F. Morton, San Diego, Calif. (US); Clark A. Sehon, West Chester, Pa. (US); and Nigel P. Shankley, Solana Beach, Calif. (US)
Assigned to Janssen Pharmaceutica, N.V., Beerse (Belgium)
Filed on Sep. 19, 2005, as Appl. No. 11/230,200.
Application 11/230200 is a continuation of application No. 10/612150, filed on Jul. 02, 2003, granted, now 7,037,931.
Claims priority of provisional application 60/393493, filed on Jul. 03, 2002.
Prior Publication US 2006/0014817 A1, Jan. 19, 2006
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 231/12 (2006.01); A61K 31/415 (2006.01); A61K 31/4155 (2006.01)
U.S. Cl. 548—377.1  [548/364.1; 548/364.4; 514/406] 3 Claims
 
1. A compound selected from the group consisting of 3-[5-(3,4-dichloro-phenyl)-1-(4-methoxy-phenyl)-1H-pyrazol-3-yl]-2-m-tolyl-propionate and its sodium salt.